RHRury R. Holman

Rury R. Holman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rury R. Holman has a total of 831 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    α‐Hydroxybutyrate and Cardiovascular Outcomes in People Living With Type 2 Diabetes: An EXSCEL Post Hoc Analysis

    by Afsaneh Noormandi, Faisal Aziz, Tobias Madl, Hansjörg Habisch, John B. Buse, Robert John Mentz, Abderrahim Oulhaj, Thomas R. Pieber, Svati H. Shah, Rury R. Holman, et al.

  • Open Access

    A Validated, Modifiable Proteomic Score from the EXSCEL Trial Predicts Cardiovascular Events in Diabetes

    by Kristin M. Corey, Maggie Nguyen, Michael Y. Mi, Megan E. Ramaker, Ilya Zhbannikov, Harald Sourij, G. Michael Felker, Naveed Sattar, Jennifer B. Green, Pamela S. Douglas, et al.

    Adults with type 2 diabetes mellitus (T2DM) are at increased risk for stroke, myocardial infarction, and cardiovascular death, yet individual risk is heterogeneous and incompletely captured by clinical models. In the Exenatide Study of Cardiovascular Event Lowering (EXSCEL), adults with T2DM were randomized to a GLP-1 RA (exenatide) or placebo and followed longitudinally for major adverse cardiovascular events (MACE). High-throughoput discovery proteomics was done in plasma collected at baseline and 12-months. Proteins associated with time-to-MACE were identified using multivariable regression and incorporated into supervised machine learning models. A multi-protein score was developed and externally validated in two independent population-based and trial cohorts, Cardiovascular Health Study and the Prospective Multicentre Imaging Study for Evaluation of Chest Pain (PROMISE). The proteomic score showed incremental improvement in cardiovascular risk discrimination beyond clinical factors alone, and several proteins were consistently prioritized across modeling approaches. The protein score and a top-ranked protein, tetranectin, were modified by GLP-1 RA treatment, and a decrease in the protein score was associated with improved outcomes, supporting modifiability of MACE risk. External validation confirmed generalizability across cohorts with and without diabetes. Together, these findings demonstrate that plasma proteomic signatures can enhance cardiovascular risk stratification and identify treatment-responsive biomarkers in T2DM, supporting their potential role in precision prevention strategies.

  • Open Access

    Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study

    by Katherine G. Young, Andrew P. McGovern, Rhian Hopkins, Thijs T. Jansz, Pedro M. Cardoso, Rury R. Holman, Ewan R. Pearson, Andrew T. Hattersley, Angus G. Jones, Kieran Docherty, et al.

    OBJECTIVE: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce heart failure (HF) risk in type 2 diabetes (T2D) and are recommended for patients with T2D who have atherosclerotic cardiovascular disease (ASCVD), HF, or chronic kidney disease (CKD). However, most individuals with T2D do not have these conditions, and current guidelines for this group do not indicate which individuals may benefit most from SGLT2i. We aimed to develop and validate a model to predict the individual-level HF benefit of SGLT2i in individuals with T2D without ASCVD, HF, or CKD. RESEARCH DESIGN AND METHODS: We developed the SGLT2i Absolute Benefit Response (SABRE) model, combining absolute HF risk from the validated QDiabetes-HF model with the SGLT2i-associated hazard ratio (HR) for HF hospitalization from a trial meta-analysis (HR 0.63) to estimate individual 5-year HF benefit. Model components and predictions were validated using U.K. primary care data with linked hospital and death records from 2013 to 2020. RESULTS: Among 57,368 SGLT2i initiators and 111,673 comparator (dipeptidyl peptidase 4 inhibitor or sulfonylurea) initiators, SGLT2i use was associated with a 30% lower risk of new-onset HF (HR 0.70 [95% CI 0.63–0.78]), consistent with trial evidence. Relative HF benefit did not vary by baseline absolute HF risk (P = 0.82). The SABRE model–predicted 5-year absolute HF benefit with SGLT2i ranged from <0.1% to 14.1% (median 1.0% [interquartile range 0.6–1.8%]) and calibrated well against observed HF outcomes. SABRE provided more targeted HF prevention than current guidelines in those with T2D without ASCVD, HF, or CKD. CONCLUSIONS: The SABRE model is an easily deployed clinical prediction model integrating trial evidence and allowing more precise targeting of SGLT2i for primary HF prevention in T2D.

  • Open Access

    Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study

    by Laura M. Güdemann, Katherine G. Young, Pedro Cardoso, Bilal A. Mateen, Rury R. Holman, Naveed Sattar, Ewan R. Pearson, Andrew T. Hattersley, Angus G. Jones, Beverley M. Shields, et al.


  • The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review

    by Ashni Goshrani, Rose Lin, Leonid Churilov, Michele Gaca, Christine Sommerville, Andrew Farmer, Kamlesh Khunti, Elizabeth Holmes-Truscott, Negar Naderpoor, David O’NEal, et al.

    BACKGROUND: Adaptive and master protocol clinical trials offer significant advantages for diabetes research, including enhanced efficiency and personalized treatment strategies. PURPOSE: This scoping review aimed to systematically map the use of adaptive and master protocol designs in interventional trials for type 1 and type 2 diabetes, identify research gaps, and highlight opportunities for broader implementation. DATA SOURCES: A systematic literature search was performed using MEDLINE, Embase, CENTRAL, Emcare, Global Health, Web of Science, and clinical trial registries. Gray literature searches complemented database findings. STUDY SELECTION: Studies using adaptive, platform, basket, or umbrella trial designs in people with type 1 or type 2 diabetes were included. DATA EXTRACTION: Data were charted using a standardized form. Extracted variables included diabetes type, trial design, adaptive features, interventions, end points, and key findings. DATA SYNTHESIS: Of 396 articles screened, 6 published adaptive trials met the inclusion criteria: 3 in type 1 diabetes, 1 in type 2 diabetes, and 2 in diabetes-related neuropathy. Most used adaptive features for dose finding, response-adaptive randomization, and sample size reestimation. No published platform, basket, or umbrella trials were identified. Six ongoing adaptive trials in type 1 diabetes were identified through registry searches, four under an adaptive platform master protocol. LIMITATIONS: Despite a comprehensive search, some gray literature and unpublished studies may have been missed. Risk of bias was not assessed, consistent with scoping review methodology. CONCLUSIONS: Adaptive and master protocol trials remain rare in diabetes. Overcoming barriers through targeted training and awareness, robust regulatory frameworks, and strategic incentives could support broader adoption.

  • Open Access

    Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study

    by Katherine G Young, Andrew P McGovern, Rhian Hopkins, Thijs T Jansz, Pedro M Cardoso, Rury R Holman, Ewan R Pearson, Andrew T Hattersley, Angus G Jones, Kieran Docherty, et al.

    Objectives To develop and validate a model to predict individual-level benefits of SGLT2-inhibitors for heart failure prevention in people with type 2 diabetes who do not have atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic kidney disease (CKD). Design Population based cohort study. Setting The SGLT2-inhibitor absolute response (SABRE) model estimated individual-level 5-year heart failure benefits using absolute heart failure risk predictions from the previously validated QDiabetes-Heart Failure model, combined with the hazard ratio of SGLT2i-associated hospitalisation for heart failure benefit (HR: 0.63 [95% CI: 0.50 to 0.80]) from trial meta-analysis. The data source was primary care records with linked hospital admission and death records (Clinical Practice Research Datalink, England) from January 2013 to October 2020. Population Adults with T2D without ASCVD, HF or CKD initiating an SGLT2i (n=57,368) or, as a comparator group, DPP4-inhibitors or sulfonylureas (n=111,673). Propensity score weighting and regression adjustment were used to mitigate potential treatment selection bias. Validation of model accuracy was performed by comparing the calibration of predicted versus observed heart failure benefits in those receiving SGLT2i versus comparator therapy. Main outcome measures New-onset heart failure recorded in primary care, linked hospital or death records. Results Amongst 57,368 SGLT2i and 111,673 DPP4i/SU treatment initiations, estimated risk of new-onset heart failure was 30% lower with SGLT2i versus the comparator arm (HR: 0.70 [95% CI: 0.63 to 0.78]), similar to trial meta-analysis for hospitalisation for heart failure. The relative benefit of SGLT2i on heart failure was consistent across all levels of baseline absolute heart failure risk as estimated from the QDiabetes-Heart Failure model (p=0.82 for treatment arm:baseline heart failure risk interaction). 5-year absolute heart failure benefit predictions with SGLT2i ranged from Conclusions SGLT2i can be targeted to individuals with type 2 diabetes without ASCVD/HF/CKD for primary prevention of heart failure using an easily deployed clinical prediction model integrating evidence from clinical trials.

  • International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL

    by Philip M. Clarke, Xinyang Hua, Ruth L. Coleman, John Chalmers, Mark Woodward, Jennifer B. Green, Darren K. McGuire, Lee-Ling Lim, Amanda I. Adler, Rury R. Holman

    OBJECTIVE: To examine differences in case-fatality incidence among individuals with type 2 diabetes after major coronary or cerebrovascular events by geographic region and country income level. RESEARCH DESIGN AND METHODS: We studied ADVANCE, TECOS, and EXSCEL participants who experienced within-trial major coronary (fatal or nonfatal myocardial infarction or sudden cardiac death) or cerebrovascular (fatal or nonfatal stroke) events. Case fatality was defined as death at the time or within 30 days of an event. We compared geographic regions with the reference category (Western Europe, North America, or Australia and New Zealand) and compared medium- and low-income countries, based on gross national income per capita by the World Bank, with the reference category (high). Unadjusted and adjusted analyses were performed for each trial using logistic regression for individual participant data, and the results were meta-analyzed. Adjustments were made for previous cardiovascular events and risk factors. RESULTS: There were 2,574 major coronary and 1,247 cerebrovascular events among the 40,563 study participants. Postcoronary case-fatality adjusted odds ratios (95% CIs), compared with the reference group, were 3.31 (2.32–4.72), 2.78 (2.11–3.66), and 2.84 (1.71–4.73) for Asia, Central and Eastern Europe, and South America and Africa, respectively. The odds ratio for low- and middle-income versus high-income countries was 3.07 (2.41–3.92). Case fatality after a major cerebrovascular event did not differ by geographic region or income group. CONCLUSIONS: Postcoronary case fatality was substantially higher in Asia, Central and Eastern Europe, and South America and Africa compared with Western countries and higher in low- and middle-income countries compared with high-income countries.

  • Open Access

    Validation of a treatment selection algorithm for optimal choice of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups

    by Laura M Guedemann, Katherine G Young, Pedro Cardoso, Bilal A Mateen, Rury R Holman, Naveed Sattar, Ewan R Pearson, Andrew T Hattersley, Angus G Jones, Beverley M Shields, et al.

    Background: Targeting type 2 diabetes treatments based on the routine clinical features of individual patients represents a practical precision medicine approach with potential worldwide applicability. We aimed to evaluate a recently proposed treatment selection model predicting differences in glycaemic responses to SGLT2-inhibitors and DPP4-inhibitors across major UK ethnicity groups. Methods: We externally validated the SGLT2i-DPP4i model in UK primary care cohort (CPRD Aurum, 2013-2020) independent of the original model development cohort. Non-insulin treated individuals with type 2 diabetes were identified and categorised by major UK ethnicity groups: White, Black, South Asian and Mixed/Other. For each ethnicity group, we applied a closed testing procedure to assess whether model recalibration was required. After model updates, we assessed the calibration accuracy of predicted differences in glycaemic response (6-month change in HbA1c) between SGLT2i and DPP4i for each ethnicity group. Results: SGLT2i (n=57,749) and DPP4i (n=87,807) initiations were identified amongst people of White (n=114,287; 78.5%), Black (n=6,663; 4.6%), South Asian (n=20,969; 14.4%) and Mixed/Other (n=3,637; 2.5%) ethnicities. Minor model adjustment was required to adjust for greater observed than predicted glycaemic responses to DPP4i (White -1.6 mmol/mol; Black -3.0 mmol/mol; South Asian -2.6 mmol/mol; Mixed/Other -2.6 mmol/mol). SGLT2i predictions did not require adjustment for non-White ethnicity groups. After model updates, average predicted HbA1c reduction was 3.7 mmol/mol (95%CI 3.5-3.9) greater with SGLT2i than DPP4i for those of White ethnicity; this was greater than for those of South Asian (2.1 mmol/mol (95%CI 1.6-2.6)), Black (0.6 mmol/mol (95%CI 0.5-1.7)) and Mixed/Other (2.6 mmol/mol (95%CI 1.4-3.8)) ethnicity groups. For all ethnicity groups, calibration of predicted differential glycaemic treatment effects were well-calibrated. Conclusion: A treatment selection model for SGLT2-inhibitor and DPP4-inhibitor therapies is accurate for all major UK ethnicity groups. Simple recalibration is beneficial to optimise performance and this is recommended prior to deployment of the model in new populations and settings.

  • Open Access

    Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects

    by Jessica Chadwick, Colin Berry, Meredith A. Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A. Hinterberg, Rury R. Holman, Matthew M.Y. Lee, Torbjørn Omland, Clare Paterson, et al.

    Recognition of benefits and adverse effects of therapies in earlier clinical trial phases could improve the safety, efficiency, and cost of clinical trials. Using four clinical trials representing a diverse set of diseases and drug classes (EXSCEL: exenatide/GLP‐1 RA, SUGAR‐DM‐HF: empagliflozin/SGLT2i, PRADA: epirubicin/anthracycline, and AMPLE: abatacept/immunomodulator and adalimumab/TNF inhibitor), we hypothesized that previously validated proteomic measures for cardiometabolic outcomes could enable the detection of beneficial and adverse drug effects in fewer participants over a shorter follow‐up period. Changes in SomaSignal TM proteomic tests over time in response to treatment were assessed in the EXSCEL (baseline vs 1 year; once‐weekly exenatide (EQW) (n) = 1812 vs control (n) = 1787), SUGAR‐DM‐HF (baseline vs 12 weeks and 36 weeks; empagliflozin (n) = 45 vs control (n) = 52), AMPLE (baseline vs 85 days and 1 year; abatacept (n) = 210, adalimumab (n) = 222), and PRADA (baseline vs 7‐10 days and 3 months, n = 120) trial. Improvement of cardiovascular risk and cardiometabolic traits with EQW was detectable within 1 year ( P = .002) in sample sizes significantly smaller than the original study. Cardio‐ and kidney‐protective ( P = .06, P = .037) effects of empagliflozin were detectable within 36 weeks in a small sample size (n ∼ 50). Abatacept and adalimumab treatment demonstrated significant improvements in cardiovascular risk ( P ≤ .001, P ≤ .001) and cardiorespiratory fitness ( P ≤ .001, P ≤ .001) within 85 days. In contrast, anthracycline treatment led to significant increases in heart failure mortality risk ( P ≤ 0.001) and cardiovascular risk ( P = .004) after the first cycle of chemotherapy treatment. These findings provide preliminary evidence that proteomics may provide a powerful tool for optimizing drug pipelines by predicting the effects of novel therapeutics in smaller, shorter trials.


  • Open Access

    Leveraging External Controls in Clinical Trials: Estimands, Estimation, Assumptions

    by Bo Liu, Laine Thomas, Rury R. Holman, Fan Li

    It is increasingly common to augment randomized controlled trial with external controls from observational data, to evaluate the treatment effect of an intervention. Traditional approaches to treatment effect estimation involve ambiguous estimands and unrealistic or strong assumptions, such as mean exchangeability. We introduce a double-indexed notation for potential outcomes to define causal estimands transparently and clarify distinct sources of implicit bias. We show that the concurrent control arm is critical in assessing the plausibility of assumptions and providing unbiased causal estimation. We derive a consistent and locally efficient estimator for a class of weighted average treatment effect estimands that combines concurrent and external data without assuming mean exchangeability. This estimator incorporates an estimate of the systematic difference in outcomes between the concurrent and external units, of which we propose a Frish-Waugh-Lovell style partial regression method to obtain. We compare the proposed methods with existing methods using extensive simulation and applied to cardiovascular clinical trials.